Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flotex-C
- Development stage
- Preclinical
- Lead developer
- Incannex Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flotex-C is a preclinical-stage sustained-release oral capsule formulation of a cannabinoid, developed by APIRx Pharma Sciences (also known as Apixir Pharma Sciences). The drug is designed to provide extended exposure to the active cannabinoid ingredient, potentially improving therapeutic outcomes and patient compliance for various unmet medical indications. As of early 2024, the specific cannabinoid molecule and the targeted clinical indications have not been publicly disclosed, and the product remains in the preclinical phase with patent applications pending. It is part of APIRx's broader portfolio of cannabinoid-based delivery systems intended for controlled release.
Beyond the preview
Go deeper on Flotex-C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flotex-C.